Ng Ka Wai, Chaturvedi Nandita, Coté Gerard L, Fisher Stephanie A, Mabbott Samuel
Department of Biomedical Engineering, Texas A&M University, 600 Discovery Drive, College Station, TX, 77840-3006, USA.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Commun Med (Lond). 2024 Oct 22;4(1):208. doi: 10.1038/s43856-024-00642-4.
Preeclampsia is a multi-organ pregnancy complication, that is primarily detected when pregnant people have high blood pressure, and is confirmed by testing for the presence of protein in the urine. While more specific and accurate diagnostic and imaging tests are becoming available, they are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care. Since biochemical processes are a precursor to the systemic progression of disease, we review some established, emerging, and promising biomarkers that are proposed to be associated with preeclampsia, and newly developed approaches for screening them at the point of care, to reduce the burden of the disease.
子痫前期是一种多器官妊娠并发症,主要在孕妇出现高血压时被检测到,并通过检测尿液中是否存在蛋白质来确诊。虽然更特异、准确的诊断和成像检测方法正在出现,但它们仍处于广泛监管采用的过程中,因此尚未成为标准治疗手段。由于生化过程是疾病全身进展的先兆,我们综述了一些已确立的、新兴的和有前景的生物标志物,这些生物标志物被认为与子痫前期有关,以及新开发的即时护理筛查方法,以减轻该疾病的负担。